Treatment strategies have not been well established for thrombotic microangiopathy associated with malignant hypertension.

Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in ...

Sacubitril/valsartan may be a better treatment option compared with ACEi/ARBs for patients with malignant hypertension-associated thrombotic microangiopathy. Kidney recovery is better when ...

Implantable cardioverter-defibrillators were no better than amiodarone for survival in chronic Chagas cardiomyopathy, though ...

Biocon Pharma, a wholly owned subsidiary of the company, has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the USFDA.

“That was most clearly and recently seen with sacubitril/valsartan.” In contrast, the benefits of SGLT2 inhibitors are consistent across the entire spectrum of LVEF, investigators note. The analysis ...

Novartis, Pfizer, Otsuka and Novo Nordisk have been called out by the UK’s Prescription Medicines Code of Practice Authority (PMCPA) for breaching the Association of the British Pharmaceutical ...

How did a cardiologist get to go to space in August? (Space.com) The Heart Rhythm Society put out a statement stressing that ...

AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that have to be delivered via a needle.

Researchers have established that sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is not superior to enalapril in the treatment of heart failure (HF) in children who have ...